MRC1 and neoplasm: A recent study also suggested that targeting the angiogenic factor, fibroblast growth factor 2 (FGF2), in combination with radiotherapy can increase the iNOS+/CD206+ TAM ratio and improve tumor responses following fractionated radiotherapy (75).